American College of Radiology and National Kidney Foundation publish cross-discipline guidance on administering iodinated contrast media in patients with kidney disease.
Higher cerebrospinal fluid gadolinium concentrations were detected within the first eight hours after gadolinium-based contrast agent administration.
Patients on hemodialysis had significantly higher DN and GP signal intensity increase.
Pediatric patients were more likely to consume prescribed dose of Breeza than barium sulfate suspension.
There is high diagnostic accuracy when grading gliomas with dynamic contrast material–enhanced (DCE) and dynamic susceptibility contrast (DSC) MR imaging.
The number of adverse events related to contrast-enhanced CT are not statistically different between patients who fasted or who ate beforehand.
Both nonionic iodinated contrast medium and gadolinium-based contrast medium rarely cause allergic-like reactions.
As with any drug, radiologists need to consider the benefit-risk profile of anything given to a patient, and GBCAs are no exception.
Supplemental imaging with CEDM may help detect cancer among women at high risk for cancer.
Recent FDA review process of inconclusive clinical studies creates a potentially unhealthy decision-making environment for patients needing gadolinium-enhanced MRIs.